FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. PA/4-33288A APPLICATION NO. 10/565,455 APPLICANT AZRIA ET AL. FILING DATE April 5, 2006

Group

| U.S. PATENT DOCUMENTS | | | | | | | | | | | |
|--|-------------------------|---|----------|--------|-------|----------|--------------|---------------|--|--|--|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILII | NG DATE | | | |
| | AA | | | | | | | | | | |
| | AB | | | | | | | | | | |
| | AC | | | | | | | | | | |
| | AD | | | | | | | | | | |
| | AE | | | | | | | | | | |
| | AF | | | | | | | | | | |
| | AG | | | | | | | | | | |
| | АН | | | | | | | | | | |
| | ΑI | | | | | | | | | | |
| | AJ | | | | | | | | | | |
| | AK | | | | | | | | | | |
| | AL | | | | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | |
| | | DOCUMENT NUMBER | DATE | OFFICE | CLASS | SUBCLASS | TRAN: YES | SLATION NO | | | |
| | AM | 00/59863 | 10/12/00 | wo | | | | | | | |
| | AN- | 05 345729 | 12/27/93 | JP | | | | | | | |
| | AO | | | | | | | | | | |
| | AP | | | | | | | | | | |
| | AQ | | | | | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.) | | | | | | | | | | | |
| | AR | Mongiorgi et al., "Influence of Calcitonin Treatment on the Bone Structure and Mineral Content in Osteoarthritis", Bollettino Societa Italiana Biologia Sperimentale, Vol. 68, No. 2, pp. 85-89 (1992). | | | | | | | | | |
| | AS | Gospodinoff et al., "Calcitonin in Treatment of Coxarthrosis", Clinica Terapeutica, Vol. 110, No. 2, pp. 129-133 (1984). | | | | | | | | | |
| | АТ | Consoli et al., "Calcitonin in Rheumatologie Osteoporosis Aspects and Prelimin Evaluation of Pathophysiology and Clinical Features", Clinica Terapeutica, Vol. 118, No. 1, pp. 37-47 (1986). | | | | | | | | | |
| FXAMIN | (AMINER DATE CONSIDERED | | | | | | | | | | |

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. PA/4-33288A APPLICATION NO. 10/565,455 APPLICANT AZRIA ET AL. FILING DATE April 5, 2006

Group

| EXAMINER INITIAL | OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.) | | | | | | | |
|---------------------|--|--|--|--------------------------|--|--|--|--|
| | ва | Guggi et al., "In Vitro Evaluation of Polymeric Excipients Protecting Calcitonin Against Degradation by Intestinal Serine Proteases", International Journal of Pharmaceutics, Vol. 252, No. 1-2, pp. 187-196 (2003); Database Medline 'Online', Abstract Database Accession No. NLM12550794. | | | | | | |
| | ВВ | Smethurst et al., "Combined Therapy in Paget's Disease", ACTA Vitaminolo | with Ascorbic Acid and Calcitonin for the Relief of Bone Pain agica et Enzymologica, Vol. 3, No. 1, pp. 8-11 (1981). | | | | | |
| | вс | Lee et al., "Oral Delivery of Salmon C pp. 225-238 (2000). | alcitonin", Advanced Drug Delivery F | Reviews, Vol. 42, No. 3, | | | | |
| | BD | | | | | | | |
| | BE | | | ! | | | | |
| | BF | | | : | | | | |
| | ВG | | | | | | | |
| | вн | | | | | | | |
| · | ВІ | | | : | | | | |
| | BJ | | | | | | | |
| | вк | | | · · | | | | |
| | BL. | | | | | | | |
| | вм | | | | | | | |
| | BN | | | ; | | | | |
| EXAMINER | | | DATE CONSIDERED | , | | | | |

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.